APVO: Rega marang dodolan Aptevo Therapeutics, Inc.
Aptevo Therapeutics (APVO) is expanding its presence in the immuno-oncology segment by implementing bispecific antibodies via the ADAPTIR system. The price-to-sales ratio illustrates the business valuation trend, where the latest parameter stands at 2.90. The company's operations rely on external investments and grants due to a lack of profitability. Critically low liquidity combined with the complexity of clinical trials creates significant operational threats.
Rincian analitis perusahaan Aptevo Therapeutics (APVO)
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- statistik kawajiban utang lan likuiditas:
Utang Agregat marang Modal Aptevo Therapeutics|APVO - Utang jangka dawa marang modal|Kewajiban jangka cendhak marang modal aptevotherapeutics.com|APVO - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Aptevo|APVO - Utang jangka dawa perusahaan|Utang jangka cendhak Aptevo Therapeutics|Rasio jangkoan perantara aptevotherapeutics.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
APVO - Penghasilan resik|Bathi resik mangsa ngarep Aptevo Therapeutics|APVO - Pangali P/E|Pangali mangsa ngarep rega marang bathi aptevotherapeutics.com|APVO - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Aptevo|APVO - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajroning taun lumaku Aptevo Therapeutics|APVO - Bathi resik saben saham (EPS TTM)|Wutah bathi EPS kuartalan aptevotherapeutics.com|APVO - Wutah bathi saben saham ing taun lumaku|Prakiraan owah-owahan bathi resik saben saham kanggo taun ngarep Aptevo Therapeutics
- data total pendapatan lan volume dodolan:
Ringkesan analitik perusahaan:Aptevo Therapeutics, Inc. APVO
To balance capital risks and returns in biotech, Aptevo Therapeutics (APVO) finds the assessment of market value relative to actual sales critically important. By analyzing the P/S trajectory, an investor determines the extent to which the market overvalues the potential of the ADAPTIR platform in the cancer immunotherapy segment, comparing market capitalization with current revenue to confirm the fundamental stability of the business.
Pesaing Aptevo Therapeutics
argenx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BNTX (BioNTech)|Abivax Pharma (ABVX) - Rega marang dodolan|ADMA Bio - Multiplikator P/S|PTGX - Multiplikator P/S|Immunovant, Inc. (IMVT) - Rasio rega marang pendapatan|Rasio rega marang dodolan KNSA (kiniksa.com)|Kapitalisasi marang pendapatan GRFS|ADPT (Adaptive Biotech) - Kapitalisasi marang volume dodolan|Multiplikator P/S CLDX|AUPH - Rega marang dodolan|BioCryst - Kapitalisasi marang pendapatan|veratx.com - Rasio rega marang pendapatan|DNTH - Rasio rega marang pendapatan|Rega marang dodolan Pharvaris NV|ABCL (AbCellera Biologics Inc) - Kapitalisasi marang pendapatan|Tourmaline - Rasio kapitalisasi pasar marang pendapatan|Kapitalisasi marang pendapatan PGEN|PHAR (pharming.com) - Kapitalisasi marang volume dodolan|Multiplikator P/S NKTR|UPB (Upstream Bio, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ZBIO (Zenas Biopharma, Inc.)|Immunome Bio (IMNM) - Rega marang dodolan|GOSS - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan KALV (kalvista.com)|SEPN: Multiplikator P/S|Pieris Pharma (PVLA) - Multiplikator P/S|Rasio rega marang pendapatan Savara Corp|Rigel Corp - Rasio rega marang dodolan|Multiplikator P/S ANAB|ATXS - Rega marang dodolan|enGene - Kapitalisasi marang pendapatan|Multiplikator P/S RAPT Therapeutics Inc. RAPT|JBIO: Kapitalisasi marang pendapatan|Aclaris Therapeutics, Inc - Kapitalisasi marang volume dodolan|KYTX: Multiplikator P/S|TLSA - Koefisien rega marang pendapatan|CABA (Cabaletta Bio) - Multiplikator P/S|Kapitalisasi marang pendapatan Ventyx Biosciences Inc. (VTYX)|Rasio rega marang pendapatan Theratechnologies Inc (THTX)|Koefisien rega marang pendapatan Avalo Therapeutics Inc|Multiplikator P/S ELDN (Eledon Pharmaceuticals)|Multiplikator P/S agenusbio.com AGEN|CLYM - Rasio rega marang pendapatan|Rasio rega marang dodolan ZURA|ATYR (aTyr) - Kapitalisasi marang pendapatan|ADAG (Adagene Inc.) - Rasio rega marang pendapatan|Rasio rega marang pendapatan ImageneBio|Rega marang dodolan Shattuck Therapeutics STTK|Rasio rega marang pendapatan Equillium, Inc. (EQ)|CNTB: Rasio rega marang dodolan|Multiplikator P/S IMUX (Immunic)|Rasio kapitalisasi pasar marang pendapatan ATRA|InflaRx GmbH - Multiplikator P/S|XFOR - Multiplikator P/S|adicetbio.com (ACET) - Rasio rega marang pendapatan|Celularity - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan INmune Bio Corp|Kapitalisasi marang pendapatan Barinthus Biotherapeutics Corp (BRNS)|Multiplikator P/S KZR|Multiplikator P/S sabbiotherapeutics.com (SABS)|Akari Therapeutics Plc - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ENLV|Q32 Bio Corp - Multiplikator P/S|Koefisien rega marang pendapatan GeoVax Corp GOVX|Edesa Biotech, Inc. (EDSA) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan ibioinc.com|Rasio rega marang pendapatan Carisma Therapeutics Inc|Kapitalisasi marang pendapatan XTL Biopharmaceuticals Ltd (XTLB)|Kapitalisasi marang pendapatan BOLT (Bolt Biotherapeutics)|Multiplikator P/S hcwbiologics.com (HCWB)|Rasio rega marang pendapatan AIM ImmunoTech Inc. AIM|ADTX: Rasio kapitalisasi marang pendapatan|GRI Bio - Multiplikator P/S|Rega marang dodolan XORTX Therapeutics Inc|HIND: Multiplikator P/S|Revelation Biosciences Corp (REVB) - Multiplikator P/S|Rasio rega marang pendapatan Indaptus Therapeutics|scinai.com - Rasio rega marang dodolan|Kapitalisasi marang pendapatan CALI (CalciMedica, Inc.)|Kapitalisasi marang volume dodolan AFMD|Multiplikator P/S ALLK (Allakos)|HOOKIPA Pharma, Inc. (HOOK) - Rega marang dodolan|IGMS: Kapitalisasi marang pendapatan|ITOS: Rasio rega marang pendapatan|Ocean Biomedical (OCEA) - Rasio rega marang pendapatan|Rega marang dodolan TC BioPharm (Holdings) Plc (TCBP)|Kapitalisasi marang pendapatan THRD
